T
Todd R. Golub
Researcher at Harvard University
Publications - 454
Citations - 234100
Todd R. Golub is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Gene expression profiling. The author has an hindex of 164, co-authored 422 publications receiving 201457 citations. Previous affiliations of Todd R. Golub include Rush University Medical Center & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
Jennifer A. Perry,Adam Kiezun,Peter Tonzi,Eliezer M. Van Allen,Eliezer M. Van Allen,Scott L. Carter,Sylvan C. Baca,Sylvan C. Baca,Glenn S. Cowley,Ami S. Bhatt,Ami S. Bhatt,Esther Rheinbay,Chandra Sekhar Pedamallu,Chandra Sekhar Pedamallu,Elena Helman,Elena Helman,Amaro Taylor-Weiner,Aaron McKenna,David S. DeLuca,Michael S. Lawrence,Lauren Ambrogio,Carrie Sougnez,Andrey Sivachenko,Loren D. Walensky,Nikhil Wagle,Jaume Mora,Carmen de Torres,Cinzia Lavarino,Simone dos Santos Aguiar,José Andrés Yunes,Silvia Regina Brandalise,Gabriela Elisa Mercado-Celis,Jorge Melendez-Zajgla,Rocío Cárdenas-Cardós,Liliana Velasco-Hidalgo,Charles W. M. Roberts,Levi A. Garraway,Carlos Rodriguez-Galindo,Stacey Gabriel,Eric S. Lander,Eric S. Lander,Todd R. Golub,Todd R. Golub,Stuart H. Orkin,Stuart H. Orkin,Gad Getz,Gad Getz,Katherine A. Janeway +47 more
TL;DR: In this paper, the authors examined 59 tumor/normal pairs by whole-exome, whole-genome, and RNA-sequencing, and found that only the TP53 gene was mutated at significant frequency across all samples.
Journal ArticleDOI
Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.
Steven M. Corsello,Steven M. Corsello,Rohith T. Nagari,Ryan Spangler,Jordan Rossen,Mustafa Kocak,Jordan Bryan,Jordan Bryan,Ranad Humeidi,David Peck,Xiaoyun Wu,Anna Tang,Vickie M. Wang,Sam Bender,Evan Lemire,Rajiv Narayan,Philip Montgomery,Uri Ben-David,Uri Ben-David,Colin W. Garvie,Yii-Der Ida Chen,Matthew G. Rees,Nicholas J. Lyons,James M. McFarland,Bang Wong,Li Wang,Nancy Dumont,Patrick O'Hearn,Eric Stefan,Eric Stefan,John G. Doench,Caitlin N. Harrington,Heidi Greulich,Matthew Meyerson,Matthew Meyerson,Francisca Vazquez,Ayshwarya Subramanian,Jennifer Roth,Joshua Bittker,Joshua Bittker,Jesse S. Boehm,Christopher C. Mader,Aviad Tsherniak,Todd R. Golub +43 more
TL;DR: An unexpectedly large number of non-oncology drugs selectively inhibited subsets of cancer cell lines in a manner predictable from the cell lines' molecular features.
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence,Petar Stojanov,Craig H. Mermel,James T. Robinson,Levi A. Garraway,Todd R. Golub,Matthew Meyerson,Stacey Gabriel,Eric S. Lander,Gad Getz +9 more
TL;DR: In this paper, the authors explored the feasibility of creating a comprehensive catalogue of cancer genes by analyzing exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types and found that large-scale genomic analysis can identify nearly all known cancer genes in these tumour types.
Journal ArticleDOI
Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma
Richard Smith,Leah A. Owen,Deborah J. Trem,Jenny S. Wong,Jennifer Whangbo,Todd R. Golub,Todd R. Golub,Stephen L. Lessnick,Stephen L. Lessnick +8 more
TL;DR: It is shown that ongoing EWS/FLI expression is required for the tumorigenic phenotype of Ewing's sarcoma by combining retroviral-mediated RNA interference with reexpression studies, and a highly validated transcriptional profile for the EWS-FLI fusion protein is developed.
Journal ArticleDOI
microRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors
Jun Lu,Shangqin Guo,Benjamin L. Ebert,Benjamin L. Ebert,Benjamin L. Ebert,Hao Zhang,Xiao Peng,Jocelyn Bosco,Jennifer Pretz,Rita Schlanger,Judy Y. Wang,Raymond H. Mak,David Dombkowski,Frederic I. Preffer,David T. Scadden,Todd R. Golub,Todd R. Golub,Todd R. Golub +17 more
TL;DR: It is reported here that miR-150 modulates lineage fate in MEPs, and thus establishes a role for miRNAs in lineage specification of mammalian multipotent cells.